State of Wyoming Makes New $549,000 Investment in Septerna, Inc. $SEPN

State of Wyoming purchased a new stake in Septerna, Inc. (NASDAQ:SEPN) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 16,379 shares of the company’s stock, valued at approximately $549,000.

Several other large investors also recently bought and sold shares of the company. Group One Trading LLC increased its position in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after purchasing an additional 8,955 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in Septerna during the fourth quarter worth about $35,000. Russell Investments Group Ltd. acquired a new stake in shares of Septerna during the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new position in Septerna in the fourth quarter valued at approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Septerna in the fourth quarter worth approximately $61,000.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Wells Fargo & Company raised their target price on Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. JonesTrading increased their price target on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. Truist Financial boosted their price objective on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Septerna has an average rating of “Moderate Buy” and an average target price of $51.33.

Septerna Price Performance

SEPN stock opened at $44.20 on Tuesday. The business’s 50-day moving average is $36.11 and its two-hundred day moving average is $29.80. The firm has a market capitalization of $2.06 billion, a P/E ratio of -81.85 and a beta of 2.29. Septerna, Inc. has a 1 year low of $10.74 and a 1 year high of $51.10.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. The firm had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. On average, analysts expect that Septerna, Inc. will post -1.36 EPS for the current year.

Insider Buying and Selling at Septerna

In other news, insider Samira Shaikhly sold 2,178 shares of Septerna stock in a transaction on Monday, June 29th. The shares were sold at an average price of $35.18, for a total transaction of $76,622.04. Following the completion of the sale, the insider directly owned 793 shares of the company’s stock, valued at approximately $27,897.74. The trade was a 73.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Elizabeth Bhatt sold 25,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $7,665,196. This represents a 12.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 72,828 shares of company stock valued at $2,684,314. Insiders own 5.80% of the company’s stock.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.